跳到正文
原文
Nature Medicine· Georgina V. Long·· 27 天前精选AI 评分85

Relatlimab联合nivolumab对比单用nivolumab治疗晚期黑色素瘤:III期RELATIVITY-047试验5年生存及生物标志物分析

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial

AI 导读

III期RELATIVITY-047试验显示,Relatlimab联合nivolumab对比单用nivolumab治疗晚期黑色素瘤,5年无进展生存期、总生存期和黑色素瘤特异性生存率均显著改善(P<0.001),且基线LAG3高表达CD8+ T细胞与联合组疗效相关。该研究首次披露长期随访中生物标志物对预后的分层作用,为精准治疗提供依据。

推荐理由

原文明确给出III期临床试验5年随访的生存数据及生物标志物关联性,为晚期黑色素瘤治疗策略提供长期证据支持。

正文 · 原文

Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04756-1

As presented at the ESMO Congress 2026: In a 5 year follow-up of survival and correlative data from the pivotal phase 3 RELATIVITY-047 trial comparing relatlimab plus nivolumab versus nivolumab alone in patients with metastatic or unresectable melanoma, statistically significant differences in progression-free survival, overall survival and melanoma-specific survival were seen with high baseline levels of LAG3 high CD8+ T cells associated with improved response in the combination arm.

来源:Nature Medicine · nature.com